CA2417646A1 - Topical gel delivery system - Google Patents
Topical gel delivery system Download PDFInfo
- Publication number
- CA2417646A1 CA2417646A1 CA002417646A CA2417646A CA2417646A1 CA 2417646 A1 CA2417646 A1 CA 2417646A1 CA 002417646 A CA002417646 A CA 002417646A CA 2417646 A CA2417646 A CA 2417646A CA 2417646 A1 CA2417646 A1 CA 2417646A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- water
- treating
- disorder
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
Abstract
A topical aqueous gel composition is provided that has a viscosity of less than about 15,000 cP and a pH of about 3.0 to 9.0 for treating a skin disorder in a human subject. The composition consists essentially of (a) a therapeutically-effective amount of at least one compound useful for treating such a disorder, (b) a hydrophilic pharmaceutically-acceptable, polymer material such as a lightly cross-linked polyacrylic acid polymer compatible with the compound, (c) a pharmaceutically-acceptable base to adjust pH, (d) optionally a water miscible solvent, (e) optionally a preservative, (f) water, and (g) optionally an oil phase component and a suitable surfactant. The composition is useful for treating an inflammatory skin disorder, acne, or rosacea. The low viscosity composition has an advantage of being administered more accurately when combined with a container that administers the composition as drops.
Claims (6)
1. A topical aqueous gel composition having a pH of about 3 to about 9 and a viscosity of less than about 15,000 cP for treating a skin disorder in a human subject, which composition consists essentially of (a) a therapeutically-effective amount of at least one compound useful for treating such disorder, (b) a hydrophilic, pharmaceutically-acceptable, lightly cross-linked polyacrylic acid polymer compatible with the compound, (c) a pharmaceutically-acceptable base to adjust pH, (d) optionally a water miscible solvent, (e) optionally a preservative, and (f) water.
2. The composition of Claim 1, wherein the compound is an antibiotic, imidazole, retinoid, corticosteroid, or a non-steroidal anti-inflammatory drug (NSAm).
3. The composition of Claim 2, wherein the compound is an antibiotic alone or in combination with a corticosteroid or a retinoid.
4. The composition of Claim 3, wherein the compound is an antibiotic alone.
5. The composition of Claim 4, wherein the antibiotic is clindamycin phosphate.
6. The composition of Claim 5 having a pH of about 4.0 to 7.0, which composition consists essentially of (a) about 0.5% to about 2.0% w/w clindamycin phosphate, (b) about 0.1% to about 0.4% w/w of the polymer, (c) the base to adjust pH, (d) about 15.0% to about 25.0% w/w of a water miscible solvent, (e) less than about 0.2% w/w of a preservative, and (f) QSAD purified water to 100% w/w.
32.
20. The composition of Claim 19 having a pH of about 4.0 to 7.0, which composition consists essentially of (a) about 0.01% to about 0.1% w/w desonide, (b) about 0.1% to about 0.4% w/w of the polymer, (d) about 3.0% to about 10% w/w of a water miscible solvent, (e) less than about 0.25% w/w of a preservative, and (f) QSAD purified water to 100% w/w.
21. The composition of Claim 19 having a pH of about 5.0 to 6.0, which composition consists essentially of:
(a) about 0.025 to about 0.05% w/w desonide, (b) about 0.3% w/w of the polymer, (c) the base to adjust pH, (d) about 5% w/w propylene glycol, (e) about 0.2 - about 0.25% w/w methylparaben and propylparaben, and (f) QSAD purified water to 100% w/w.
22. The composition of Claim 1 in combination with a container that accurately administers a portion of the composition for topical administration to a patient.
23. The composition of Claim 22 in combination with labeling instructions for use in treating the skin disorder.
24. A method for treating a skin disorder in a human subject, which method comprises topically administering a topical aqueous gel composition having a pH of about 3 to about 9 and a viscosity of less than about 15,000 cP to an affected area of the subject's skin having such disorder in an amount and for a period of time sufficient to improve the skin disorder, wherein the composition consists essentially of 35.
(a) a therapeutically-effective amount of at least one compound useful for treating such disorder, (b) a hydrophilic pharmaceutically-acceptable lightly cross-linked polyacrylic acid polymer compatible with the pharmaceutical active material, (c) a pharmaceutically-acceptable base to adjust pH
(d) optionally a water miscible solvent, (e) optionally a preservative, and (f) water.
25. A method of preparing a topical aqueous gel composition having a viscosity of less than about 15,000.cP and a pH of about 3 to 9 useful for treating a skin disorder in a human subject, which method comprises (a) combining water with a therapeutically-effective amount of at least one compound useful for treating such disorder and a hydrophilic pharmaceutically-acceptable, lightly cross-linked polyacrylic acid polymer compatible with the compound, (b) adjusting the pH to about 3 to 9, and (c) optionally combining a water-miscible solvent, and a preservative, to form the composition.
26. The method of Claim 25, wherein the compound is an antibiotic, imidazole, retinoid, corticosteroid, or a nonsteroidal anti-inflammatory drug (NSAID).
27. The method of Claim 26, wherein the compound is an antibiotic alone or in combination with a corticosteroid or a retinoid.
28. The method of Claim 27, wherein the compound is an antibiotic alone.
29. The method of Claim 28, wherein the antibiotic is clindamycin phosphate.
30. The method of Claim 29, wherein the composition has a pH of about 4 to 7, and consists essentially of 36.
48. The composition of Claim 6, wherein the corticosteroid is desonide.
49. The composition of Claim 48, wherein the desonide is present at about 0.01 % w/w to about 1.0 % w/w.
50. The method of Claim 40, wherein the corticosteroid is desonide.
51. The method of Claim 50, wherein the desonide is present at about 0.01 % w/w to about 1.0% w/w.
52. A topical aqueous gel composition having a pH of about 3 to about 9 and a viscosity of less than about 15,000 cP for treating a skin disorder in a human subject, which composition consists essentially of (a) a therapeutically-effective amount of at least one compound useful for treating such disorder, (b) a hydrophilic pharmaceutically-acceptable, polymeric material compatible with the compound, (c) a pharmaceutically-acceptable base to adjust pH, (d) optionally a water miscible solvent, (e) optionally a preservative, and (f) water.
53. The composition of Claim 52 having a pH of about 4.0 to about 7.0, which composition consists essentially of (a) about 0.5% to about 2.0% w/w clindamycin phosphate, (b) about 0.05% to about 1.0% w/w of the polymeric material, (c) the base to adjust pH, (d) 0.0% to about 40% w/w of a water miscible solvent, (e) less than about 0.2% w/w of a preservative, and (f) purified water in a quantity sufficient to make (QSAD) 100% w/w.
54. The composition of Claim 52 having a pH of about 4 to about 7, which composition is a gel consisting essentially of (a) (i) about 0.5% to about 2% w/w clindamycin phosphate, and (ii) about 0.01% to about 0.05% w/w tretinoin;
(b) about 0.05% to about 1% w/w of the polymeric material, (c) the base to adjust pH;
(d) 0% to about 40% w/w of a water-miscible solvent;
(e) less than about 0.2% of a preservative; and (f) QSAD purified water 100% w/w.
55. A method for treating a skin disorder in a human subject, which method comprises topically administering the composition of claim 52, 53, or 54 to an affected area of the subject's skin having such disorder in an amount and for a period of time sufficient to improve the skin disorder.
56. A method of preparing the composition of claim 52, 53, or 54, which method comprises (a) combining water with a therapeutically-effective amount of at least one compound useful for treating such disorder and the polymeric material, (b) adjusting the pH to about 3 to about 9, and (c) optionally combining a water-miscible solvent and a preservative to form the composition.
57. A topical aqueous gel composition having a pH of about 3 to about 9 and a viscosity of less than about 15,000 cP for treating a skin disorder in a human subject, which comprises (a) a therapeutically-effective amount of clindamycin phosphate and tretinoin useful for treating such disorder, (b) a hydrophilic pharmaceutically-acceptable, lightly cross-linked polyacrylic acid polymer compatible with the compound, (c) a pharmaceutically-acceptable base to adjust pH, (d) optionally a water miscible solvent, (e) optionally a preservative, and (f) water, wherein the clindamycin phosphate is dissolved and the tretinoin is suspended.
41.
58. The composition of Claim 57 having a pH of about 4 to about 7, which composition is a gel consisting essentially of (a) (i) about 0.5% to about 2% w/w clindamycin phosphate, and (ii) about 0.01% to about 0.05% w/w tretinoin;
(b) about 0.05% to about 1% w/w of the polymer;
(c) the base to adjust pH;
(d) 0% to about 40% w/w of a water-miscible solvent;
(e) about 0.01 to about 1% w/w of a preservative; and (f) QSAD purified water 100% w/w.
59. The composition of Claim 57 in combination with a container that accurately administers a portion of the composition for topical administration to a patient.
60. The composition of Claim 59 in combination with labeling instructions for use in treating the skin disorder.
61. A method for treating a skin disorder in a human subject, which method comprises topically administering the composition of claim 57 or 58 to an affected area of the subject's skin having such disorder in an amount and for a period of time sufficient to improve the skin disorder.
62. The method of Claim 61, wherein the skin disorder is an inflammatory skin disorder, acne, or rosacea.
63. The method of Claim 62, wherein the composition is administered once a day for the period of time sufficient to improve the skin disorder.
64. The method of Claim 62, wherein the skin disorder is acne.
65. A topical aqueous gel composition having a pH of about 3 to about 9 and a viscosity of less than about 15,000 cP for treating a skin disorder in a human subject, which composition consists essentially of (a) a corticosteroid at a level of about 0.01% w/w/ to about 1% w/w, (b) a hydrophilic pharmaceutically-acceptable, lightly cross-linked polyacrylic acid polymer compatible with the compound, (c) a pharmaceutically-acceptable base to adjust pH, (d) optionally a water miscible solvent, (e) optionally a preservative, and (f) water.
66. The composition of Claim 65, wherein the corticosteroid is desonide at a level of about 0.05% w/w to about 0.1% w/w and the polymeric material is present at a level of about 0.05% w/w to about 1% w/w.
67. The composition of Claim 65, wherein the corticosteroid is halobetasol propionate and the polymeric material is present art a level of about 0.05%
w/w to about 1% w/w.
68. A method for treating a skin disorder in a human subject, which method comprises topically administering the composition of claim 65, 66, or 67 to an affected area of the subject's skin having such disorder in an amount and for a period of time sufficient to improve the skin disorder.
69. A method of preparing the composition of claim 65, 66, or 67, which method comprises (a) combining water with a therapeutically-effective amount of the corticosteroid and the polymer, (b) adjusting the pH to about 3 to about 9, and (c) optionally combining the water-miscible solvent and the preservative to form the composition.
43.
32.
20. The composition of Claim 19 having a pH of about 4.0 to 7.0, which composition consists essentially of (a) about 0.01% to about 0.1% w/w desonide, (b) about 0.1% to about 0.4% w/w of the polymer, (d) about 3.0% to about 10% w/w of a water miscible solvent, (e) less than about 0.25% w/w of a preservative, and (f) QSAD purified water to 100% w/w.
21. The composition of Claim 19 having a pH of about 5.0 to 6.0, which composition consists essentially of:
(a) about 0.025 to about 0.05% w/w desonide, (b) about 0.3% w/w of the polymer, (c) the base to adjust pH, (d) about 5% w/w propylene glycol, (e) about 0.2 - about 0.25% w/w methylparaben and propylparaben, and (f) QSAD purified water to 100% w/w.
22. The composition of Claim 1 in combination with a container that accurately administers a portion of the composition for topical administration to a patient.
23. The composition of Claim 22 in combination with labeling instructions for use in treating the skin disorder.
24. A method for treating a skin disorder in a human subject, which method comprises topically administering a topical aqueous gel composition having a pH of about 3 to about 9 and a viscosity of less than about 15,000 cP to an affected area of the subject's skin having such disorder in an amount and for a period of time sufficient to improve the skin disorder, wherein the composition consists essentially of 35.
(a) a therapeutically-effective amount of at least one compound useful for treating such disorder, (b) a hydrophilic pharmaceutically-acceptable lightly cross-linked polyacrylic acid polymer compatible with the pharmaceutical active material, (c) a pharmaceutically-acceptable base to adjust pH
(d) optionally a water miscible solvent, (e) optionally a preservative, and (f) water.
25. A method of preparing a topical aqueous gel composition having a viscosity of less than about 15,000.cP and a pH of about 3 to 9 useful for treating a skin disorder in a human subject, which method comprises (a) combining water with a therapeutically-effective amount of at least one compound useful for treating such disorder and a hydrophilic pharmaceutically-acceptable, lightly cross-linked polyacrylic acid polymer compatible with the compound, (b) adjusting the pH to about 3 to 9, and (c) optionally combining a water-miscible solvent, and a preservative, to form the composition.
26. The method of Claim 25, wherein the compound is an antibiotic, imidazole, retinoid, corticosteroid, or a nonsteroidal anti-inflammatory drug (NSAID).
27. The method of Claim 26, wherein the compound is an antibiotic alone or in combination with a corticosteroid or a retinoid.
28. The method of Claim 27, wherein the compound is an antibiotic alone.
29. The method of Claim 28, wherein the antibiotic is clindamycin phosphate.
30. The method of Claim 29, wherein the composition has a pH of about 4 to 7, and consists essentially of 36.
48. The composition of Claim 6, wherein the corticosteroid is desonide.
49. The composition of Claim 48, wherein the desonide is present at about 0.01 % w/w to about 1.0 % w/w.
50. The method of Claim 40, wherein the corticosteroid is desonide.
51. The method of Claim 50, wherein the desonide is present at about 0.01 % w/w to about 1.0% w/w.
52. A topical aqueous gel composition having a pH of about 3 to about 9 and a viscosity of less than about 15,000 cP for treating a skin disorder in a human subject, which composition consists essentially of (a) a therapeutically-effective amount of at least one compound useful for treating such disorder, (b) a hydrophilic pharmaceutically-acceptable, polymeric material compatible with the compound, (c) a pharmaceutically-acceptable base to adjust pH, (d) optionally a water miscible solvent, (e) optionally a preservative, and (f) water.
53. The composition of Claim 52 having a pH of about 4.0 to about 7.0, which composition consists essentially of (a) about 0.5% to about 2.0% w/w clindamycin phosphate, (b) about 0.05% to about 1.0% w/w of the polymeric material, (c) the base to adjust pH, (d) 0.0% to about 40% w/w of a water miscible solvent, (e) less than about 0.2% w/w of a preservative, and (f) purified water in a quantity sufficient to make (QSAD) 100% w/w.
54. The composition of Claim 52 having a pH of about 4 to about 7, which composition is a gel consisting essentially of (a) (i) about 0.5% to about 2% w/w clindamycin phosphate, and (ii) about 0.01% to about 0.05% w/w tretinoin;
(b) about 0.05% to about 1% w/w of the polymeric material, (c) the base to adjust pH;
(d) 0% to about 40% w/w of a water-miscible solvent;
(e) less than about 0.2% of a preservative; and (f) QSAD purified water 100% w/w.
55. A method for treating a skin disorder in a human subject, which method comprises topically administering the composition of claim 52, 53, or 54 to an affected area of the subject's skin having such disorder in an amount and for a period of time sufficient to improve the skin disorder.
56. A method of preparing the composition of claim 52, 53, or 54, which method comprises (a) combining water with a therapeutically-effective amount of at least one compound useful for treating such disorder and the polymeric material, (b) adjusting the pH to about 3 to about 9, and (c) optionally combining a water-miscible solvent and a preservative to form the composition.
57. A topical aqueous gel composition having a pH of about 3 to about 9 and a viscosity of less than about 15,000 cP for treating a skin disorder in a human subject, which comprises (a) a therapeutically-effective amount of clindamycin phosphate and tretinoin useful for treating such disorder, (b) a hydrophilic pharmaceutically-acceptable, lightly cross-linked polyacrylic acid polymer compatible with the compound, (c) a pharmaceutically-acceptable base to adjust pH, (d) optionally a water miscible solvent, (e) optionally a preservative, and (f) water, wherein the clindamycin phosphate is dissolved and the tretinoin is suspended.
41.
58. The composition of Claim 57 having a pH of about 4 to about 7, which composition is a gel consisting essentially of (a) (i) about 0.5% to about 2% w/w clindamycin phosphate, and (ii) about 0.01% to about 0.05% w/w tretinoin;
(b) about 0.05% to about 1% w/w of the polymer;
(c) the base to adjust pH;
(d) 0% to about 40% w/w of a water-miscible solvent;
(e) about 0.01 to about 1% w/w of a preservative; and (f) QSAD purified water 100% w/w.
59. The composition of Claim 57 in combination with a container that accurately administers a portion of the composition for topical administration to a patient.
60. The composition of Claim 59 in combination with labeling instructions for use in treating the skin disorder.
61. A method for treating a skin disorder in a human subject, which method comprises topically administering the composition of claim 57 or 58 to an affected area of the subject's skin having such disorder in an amount and for a period of time sufficient to improve the skin disorder.
62. The method of Claim 61, wherein the skin disorder is an inflammatory skin disorder, acne, or rosacea.
63. The method of Claim 62, wherein the composition is administered once a day for the period of time sufficient to improve the skin disorder.
64. The method of Claim 62, wherein the skin disorder is acne.
65. A topical aqueous gel composition having a pH of about 3 to about 9 and a viscosity of less than about 15,000 cP for treating a skin disorder in a human subject, which composition consists essentially of (a) a corticosteroid at a level of about 0.01% w/w/ to about 1% w/w, (b) a hydrophilic pharmaceutically-acceptable, lightly cross-linked polyacrylic acid polymer compatible with the compound, (c) a pharmaceutically-acceptable base to adjust pH, (d) optionally a water miscible solvent, (e) optionally a preservative, and (f) water.
66. The composition of Claim 65, wherein the corticosteroid is desonide at a level of about 0.05% w/w to about 0.1% w/w and the polymeric material is present at a level of about 0.05% w/w to about 1% w/w.
67. The composition of Claim 65, wherein the corticosteroid is halobetasol propionate and the polymeric material is present art a level of about 0.05%
w/w to about 1% w/w.
68. A method for treating a skin disorder in a human subject, which method comprises topically administering the composition of claim 65, 66, or 67 to an affected area of the subject's skin having such disorder in an amount and for a period of time sufficient to improve the skin disorder.
69. A method of preparing the composition of claim 65, 66, or 67, which method comprises (a) combining water with a therapeutically-effective amount of the corticosteroid and the polymer, (b) adjusting the pH to about 3 to about 9, and (c) optionally combining the water-miscible solvent and the preservative to form the composition.
43.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/632,508 US6387383B1 (en) | 2000-08-03 | 2000-08-03 | Topical low-viscosity gel composition |
US09/632,508 | 2000-08-03 | ||
PCT/US2001/023341 WO2002011683A1 (en) | 2000-08-03 | 2001-07-24 | Topical gel delivery system |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2417646A1 true CA2417646A1 (en) | 2002-02-14 |
CA2417646C CA2417646C (en) | 2010-05-04 |
Family
ID=24535786
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2417646A Expired - Lifetime CA2417646C (en) | 2000-08-03 | 2001-07-24 | Topical gel delivery system |
Country Status (25)
Country | Link |
---|---|
US (2) | US6387383B1 (en) |
EP (2) | EP2052714B1 (en) |
JP (1) | JP4988129B2 (en) |
KR (2) | KR20080036246A (en) |
CN (2) | CN101305982B (en) |
AR (1) | AR030093A1 (en) |
AT (1) | ATE429922T1 (en) |
AU (2) | AU2001279002B2 (en) |
BE (1) | BE2013C060I2 (en) |
BR (1) | BR0113247A (en) |
CA (1) | CA2417646C (en) |
CY (3) | CY1109189T1 (en) |
DE (1) | DE60138549D1 (en) |
DK (2) | DK2052714T3 (en) |
ES (2) | ES2437321T3 (en) |
FR (1) | FR14C0053I1 (en) |
HK (1) | HK1125847A1 (en) |
LU (1) | LU92401I2 (en) |
MX (1) | MXPA03001006A (en) |
PL (1) | PL213237B1 (en) |
PT (2) | PT2052714E (en) |
RU (1) | RU2251410C2 (en) |
SI (2) | SI1304992T1 (en) |
WO (1) | WO2002011683A1 (en) |
ZA (1) | ZA200301037B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020097211A1 (en) * | 2018-11-06 | 2020-05-14 | Cote Tim | Topical compositions comprising pentoxifylline and methods of treatment using the same |
Families Citing this family (147)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020048596A1 (en) * | 1994-12-30 | 2002-04-25 | Gregor Cevc | Preparation for the transport of an active substance across barriers |
AUPN814496A0 (en) * | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
WO2000038653A1 (en) | 1998-12-23 | 2000-07-06 | Idea Ag. | Improved formulation for topical non-invasive application in vivo |
SI1031347T1 (en) | 1999-01-27 | 2002-10-31 | Idea Ag | Transnasal transport/immunisation with highly adaptable carriers |
PT1031346E (en) | 1999-01-27 | 2002-09-30 | Idea Ag | NOT INVASIVE VACCINATION THROUGH SKIN |
AU5409699A (en) * | 1999-07-05 | 2001-01-22 | Idea Ag | A method for the improvement of transport across adaptable semi-permeable barriers |
US6387383B1 (en) * | 2000-08-03 | 2002-05-14 | Dow Pharmaceutical Sciences | Topical low-viscosity gel composition |
US20060189552A1 (en) * | 2000-12-12 | 2006-08-24 | Mohan Vishnupad | Dispenser for dispensing three or more actives |
US7060732B2 (en) * | 2000-12-12 | 2006-06-13 | Imaginative Research Associates, Inc. | Antibiotic/benzoyl peroxide dispenser |
IL142037A0 (en) * | 2001-03-15 | 2002-03-10 | Agis Ind 1983 Ltd | Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug |
MXPA03009995A (en) | 2001-05-09 | 2004-06-30 | Univ Michigan | Use of compositions for treating rosacea. |
US7368122B1 (en) * | 2002-03-08 | 2008-05-06 | Dow Pharmaceutical Sciences | Skin cream |
WO2004000263A1 (en) * | 2002-06-25 | 2003-12-31 | Acrux Dds Pty Ltd | Transdermal delivery rate control using amorphous pharmaceutical compositions |
US20050186141A1 (en) * | 2002-06-25 | 2005-08-25 | Acrux Dds Pty Ltd. | Transdermal aerosol compositions |
US20050181032A1 (en) * | 2002-06-25 | 2005-08-18 | Acrux Dds Pty Ltd. | Metastable pharmaceutical compositions |
US20040171561A1 (en) * | 2002-09-03 | 2004-09-02 | Popp Karl F. | Topical formulations for treatment of rosacea |
US20040167223A1 (en) * | 2002-09-03 | 2004-08-26 | Popp Karl F. | Topical antibacterial formulations |
US6906014B2 (en) * | 2002-09-10 | 2005-06-14 | Permatex, Inc. | Stabilized topical composition |
US7473432B2 (en) * | 2002-10-11 | 2009-01-06 | Idea Ag | NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery |
US7208485B2 (en) * | 2003-01-13 | 2007-04-24 | Chemagis Ltd. | Crystalline forms of halobetasol propionate |
CA2513773C (en) | 2003-01-24 | 2013-03-26 | Connetics Australia Pty Ltd | Clindamycin phosphate foam |
CA2515293C (en) * | 2003-02-07 | 2012-03-20 | Mochida Pharmaceutical Co., Ltd. | Eicosapentaenoic acid for use in improving prognosis in the treatment of subarachnoid hemorrhage |
US20040202726A1 (en) * | 2003-04-10 | 2004-10-14 | Deshay Samuel L. | Topical blood pressure composition |
US8410102B2 (en) | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
US7439241B2 (en) | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
AR045260A1 (en) | 2003-08-12 | 2005-10-19 | 3M Innovative Properties Co | COMPOUNDS CONTAINING IMIDAZO-OXIMA REPLACED |
EP1660101A4 (en) * | 2003-08-21 | 2010-02-24 | Access Pharma Inc | Liquid formulations for the prevention and treatment of mucosal diseases and disorders |
MXPA06002199A (en) | 2003-08-27 | 2006-05-22 | 3M Innovative Properties Co | Aryloxy and arylalkyleneoxy substituted imidazoquinolines. |
WO2005023190A2 (en) | 2003-09-05 | 2005-03-17 | 3M Innovative Properties Company | Treatment for cd5+ b cell lymphoma |
BRPI0414500A (en) * | 2003-09-19 | 2006-11-07 | Drugtech Corp | pharmaceutical formulation composition to treat a vaginal infection, and methods to treat a vaginal infection, to stabilize a clindamycin formulation, to treat or prevent a recurrence of a vaginal infection in a patient and to treat vaginal conditions |
US20060140990A1 (en) * | 2003-09-19 | 2006-06-29 | Drugtech Corporation | Composition for topical treatment of mixed vaginal infections |
DE60317579T2 (en) * | 2003-09-23 | 2008-09-18 | Akciju Sabiedriba "Olainfarm" | POLYMERS 3,5-DIMETHYL-1-ADAMANTYLAMMONIUM SALT AND THEIR USE IN THE FORM OF VIRUSTATIKA |
US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
US8871782B2 (en) | 2003-10-03 | 2014-10-28 | 3M Innovative Properties Company | Alkoxy substituted imidazoquinolines |
US20050095215A1 (en) * | 2003-11-03 | 2005-05-05 | Popp Karl F. | Antimicrobial shampoo compositions |
CA2545774A1 (en) | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Oxime substituted imidazo ring compounds |
US8598192B2 (en) * | 2003-11-14 | 2013-12-03 | 3M Innovative Properties Company | Hydroxylamine substituted imidazoquinolines |
CA2547020C (en) | 2003-11-25 | 2014-03-25 | 3M Innovative Properties Company | 1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier |
WO2005066170A1 (en) | 2003-12-29 | 2005-07-21 | 3M Innovative Properties Company | Arylalkenyl and arylalkynyl substituted imidazoquinolines |
US20050139808A1 (en) * | 2003-12-30 | 2005-06-30 | Oculus Innovative Sciences, Inc. | Oxidative reductive potential water solution and process for producing same |
JP2007517044A (en) | 2003-12-30 | 2007-06-28 | スリーエム イノベイティブ プロパティズ カンパニー | Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinylsulfonamide |
WO2005065383A2 (en) * | 2003-12-30 | 2005-07-21 | Oculus Innovative Sciences, Inc. | Oxidative reductive potential water solution, processes for producing same and methods of using the same |
US20050147570A1 (en) * | 2004-01-06 | 2005-07-07 | Nordsiek Michael T. | Methods of administering diclofenac compositions for treating photodamaged skin, rosacea and/or acne |
WO2005094531A2 (en) | 2004-03-24 | 2005-10-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
US7662855B2 (en) * | 2004-05-11 | 2010-02-16 | Imaginative Research Associates, Inc. | Retinoid solutions and formulations made therefrom |
US20050255131A1 (en) * | 2004-05-11 | 2005-11-17 | Mohan Vishnupad | Clindamycin compositions and delivery system therefor |
US20060014834A1 (en) * | 2004-05-11 | 2006-01-19 | Mohan Vishnupad | Retinoid solutions and formulations made therefrom |
PL1761266T3 (en) | 2004-05-25 | 2013-09-30 | Galderma Pharma Sa | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
US8741333B2 (en) * | 2004-06-07 | 2014-06-03 | Nuvo Research Inc. | Compositions and methods for treating dermatitis or psoriasis |
US8741332B2 (en) * | 2004-06-07 | 2014-06-03 | Nuvo Research Inc. | Compositions and methods for dermally treating neuropathic pain |
US8907153B2 (en) | 2004-06-07 | 2014-12-09 | Nuvo Research Inc. | Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same |
US20070196452A1 (en) * | 2004-06-07 | 2007-08-23 | Jie Zhang | Flux-enabling compositions and methods for dermal delivery of drugs |
US8017779B2 (en) | 2004-06-15 | 2011-09-13 | 3M Innovative Properties Company | Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
FR2887149B1 (en) * | 2005-06-17 | 2007-08-03 | Galderma Sa | PROCESS FOR SOLUBILIZING THE METRONIDAZOLE |
US8026366B2 (en) | 2004-06-18 | 2011-09-27 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
WO2006065280A2 (en) | 2004-06-18 | 2006-06-22 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods |
US20070259881A1 (en) * | 2004-06-18 | 2007-11-08 | Dellaria Joseph F Jr | Substituted Imidazo Ring Systems and Methods |
WO2006038923A2 (en) | 2004-06-18 | 2006-04-13 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
ITMI20041376A1 (en) * | 2004-07-09 | 2004-10-09 | Uni Campus Bio Medico Di Roma | METHOD OF PREPARATION OF A BIOCOMPATIBLE POLYMERIC SYSTEM FOR PHARMACOLOGICAL RELEASE IN TOPICAL USE AND USE OF THE SYSTEM |
US20060093675A1 (en) * | 2004-10-29 | 2006-05-04 | Mathew Ebmeier | Intravaginal treatment of vaginal infections with metronidazole compositions |
DE602005021238D1 (en) * | 2004-11-09 | 2010-06-24 | Imaginative Res Associates Inc | RETINOID SOLUTIONS AND FORMULATIONS THEREFROM |
US20080095722A1 (en) * | 2004-11-12 | 2008-04-24 | Idea Ag | Extended Surface Aggregates in the Treatment of Skin Conditions |
WO2006074003A2 (en) | 2004-12-30 | 2006-07-13 | 3M Innovative Properties Company | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS |
JP5313502B2 (en) | 2004-12-30 | 2013-10-09 | スリーエム イノベイティブ プロパティズ カンパニー | Substituted chiral condensed [1,2] imidazo [4,5-c] cyclic compounds |
US9248127B2 (en) | 2005-02-04 | 2016-02-02 | 3M Innovative Properties Company | Aqueous gel formulations containing immune response modifiers |
WO2006086634A2 (en) | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods |
AU2006232375A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
US7943610B2 (en) | 2005-04-01 | 2011-05-17 | 3M Innovative Properties Company | Pyrazolopyridine-1,4-diamines and analogs thereof |
WO2006121429A1 (en) * | 2005-05-06 | 2006-11-16 | Imaginative Research Associates, Inc. | Clindamycin compositions and delivery system therefor |
MX2007013631A (en) * | 2005-05-09 | 2008-01-24 | Drugtech Corp | Modified-release pharmaceutical compositions. |
KR20130114229A (en) * | 2005-06-03 | 2013-10-16 | 애크럭스 디디에스 피티와이 리미티드 | Method and composition for transdermal drug delivery |
AR054805A1 (en) * | 2005-06-29 | 2007-07-18 | Stiefel Laboratories | TOPICAL COMPOSITIONS FOR SKIN TREATMENT |
CN101277699B (en) * | 2005-08-23 | 2011-01-12 | 日产化学工业株式会社 | Sustained-release preparation |
US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US20070154516A1 (en) * | 2006-01-05 | 2007-07-05 | Drugtech Corporation | Drug delivery system |
US20070224226A1 (en) * | 2006-01-05 | 2007-09-27 | Drugtech Corporation | Composition and method of use thereof |
US9107844B2 (en) * | 2006-02-03 | 2015-08-18 | Stiefel Laboratories Inc. | Topical skin treating compositions |
EP1998742A2 (en) * | 2006-03-08 | 2008-12-10 | Nuviance, INC. | Transdermal drug delivery compositions and topical compositions for application on the skin |
MX2008012526A (en) | 2006-03-31 | 2008-10-14 | Stiefel Res Australia Pyt Ltd | Foamable suspension gel. |
US20070280972A1 (en) * | 2006-04-25 | 2007-12-06 | Zars, Inc. | Adhesive solid gel-forming formulations for dermal drug delivery |
US7906506B2 (en) | 2006-07-12 | 2011-03-15 | 3M Innovative Properties Company | Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods |
RU2463038C2 (en) | 2006-10-17 | 2012-10-10 | Нуво Рисерч Инк. | Diclofenac gel |
WO2008094910A2 (en) | 2007-01-30 | 2008-08-07 | Cypress Pharmaceutical, Inc. | Hyaluronate compositions |
US20080287373A1 (en) * | 2007-05-17 | 2008-11-20 | Popp Karl F | Topical skin treating kits |
US20080312245A1 (en) * | 2007-06-12 | 2008-12-18 | Longyan Xiao | Methods and compositions for treating acne and other infectious diseases |
EP2207570A2 (en) | 2007-09-14 | 2010-07-21 | Nitto Denko Corporation | Drug carriers |
US20090098191A1 (en) * | 2007-10-16 | 2009-04-16 | Anderson Christopher G | Use of bases to stabilize transdermal formulations |
EP2214661A4 (en) * | 2007-10-18 | 2012-10-03 | Medicis Pharmaceutical Corp | Aqueous retinoid and benzoyl peroxide gel |
US20100216754A1 (en) * | 2007-11-13 | 2010-08-26 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
US20090123551A1 (en) * | 2007-11-13 | 2009-05-14 | Meritage Pharma, Inc. | Gastrointestinal delivery systems |
US20090123390A1 (en) * | 2007-11-13 | 2009-05-14 | Meritage Pharma, Inc. | Compositions for the treatment of gastrointestinal inflammation |
GB2458403B (en) | 2007-11-13 | 2010-01-13 | Meritage Pharma Inc | Stabilised corticosteroid compositions |
JP5580210B2 (en) | 2007-12-21 | 2014-08-27 | ガルデマ ラボラトリーズ インコーポレイテッド | Preoperative treatment |
US20090176719A1 (en) * | 2008-01-07 | 2009-07-09 | Liolabs Llc | Compositions and methods for treating perioral dermatitis |
BRPI0908518A2 (en) * | 2008-03-17 | 2015-09-29 | Glenmark Pharmaceuticals Ltd | stable fixed dose topical formulation and use of stable fixed dose topical formulation |
US20090264392A1 (en) * | 2008-04-21 | 2009-10-22 | Meritage Pharma, Inc. | Treating eosinophilic esophagitis |
US8853275B2 (en) * | 2008-05-16 | 2014-10-07 | Galderma Research & Development | Concurrent therapy regime/regimen for the treatment of acne related diseases |
MX2010013152A (en) | 2008-06-05 | 2011-05-02 | Dow Pharmaceutical Sciences | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent. |
AU2009264307A1 (en) * | 2008-06-24 | 2009-12-30 | Intervet International B.V. | Pharmaceutical transdermal compositions and method for treating inflammation in cattle |
WO2010047831A1 (en) * | 2008-10-23 | 2010-04-29 | Nycomed Us Inc. | Stable metronidazole gel formulations |
US9775802B2 (en) | 2009-03-24 | 2017-10-03 | Bausch & Lomb Incorporated | Method for preparing suspensions of low-solubility materials |
US20100247666A1 (en) * | 2009-03-24 | 2010-09-30 | Macleod Steven K | Method for Preparing Suspensions of Low-Solubility Materials |
US8618164B2 (en) | 2009-03-31 | 2013-12-31 | Nuvo Research Inc. | Treatment of pain with topical diclofenac compounds |
WO2010144865A2 (en) * | 2009-06-12 | 2010-12-16 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
US9364485B2 (en) | 2009-08-31 | 2016-06-14 | Dr. Reddy's Laboratories Ltd. | Topical formulations comprising a steroid |
EP2329849B1 (en) | 2009-11-18 | 2015-04-29 | Galderma Research & Development | Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder |
US8394800B2 (en) | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
ES2730411T3 (en) | 2010-03-26 | 2019-11-11 | Galderma Res & Dev | Enhanced compositions comprising brimonidine for a safe and effective treatment of telangiectasia |
HUE033143T2 (en) | 2010-03-26 | 2017-11-28 | Galderma Res & Dev | Compositions comprising brimonidine for the treatment of erythema |
WO2012001065A2 (en) | 2010-06-30 | 2012-01-05 | Galderma Research & Development | Method for preventing or treating skin tumor |
AU2011273509A1 (en) | 2010-06-30 | 2013-06-13 | Galderma Research & Development | Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor |
US8053427B1 (en) | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
CN103298451B (en) | 2010-10-21 | 2016-04-20 | 高德美国际公司 | Brimonidine gel composition and using method thereof |
US11957753B2 (en) | 2010-11-22 | 2024-04-16 | Bausch Health Ireland Limited | Pharmaceutical formulations containing corticosteroids for topical administration |
US8809307B2 (en) | 2010-11-22 | 2014-08-19 | Dow Pharmaceutical Sciences, Inc. | Pharmaceutical formulations containing corticosteroids for topical administration |
WO2013016072A1 (en) | 2011-07-22 | 2013-01-31 | Allergan, Inc. | Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases |
WO2013019974A1 (en) | 2011-08-02 | 2013-02-07 | Medicis Pharmaceutical Corporation | Compositions comprising a retinoid and a lincosamide antibiotic for use in treating rosacea |
AU2012324544B2 (en) | 2011-10-19 | 2016-11-24 | Galderma S.A. | Method for treating capillary hemangiomas |
MX2014004383A (en) | 2011-10-19 | 2014-11-12 | Galderma Sa | Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors. |
US9283217B2 (en) | 2011-11-10 | 2016-03-15 | Allergan, Inc. | Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
UA109359C2 (en) | 2011-11-10 | 2015-08-10 | TREATMENT OF SKIN DISEASES AND STATES | |
RU2548714C2 (en) * | 2012-05-03 | 2015-04-20 | Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") | Pharmaceutical composition for treating acne and method for preparing it |
US20140112959A1 (en) | 2012-10-18 | 2014-04-24 | MiCal Pharmaceuticals LLC - H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limite | Topical steroid composition and method |
RU2530644C2 (en) * | 2012-11-01 | 2014-10-10 | Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") | Comedolytic pharmaceutical composition and method for preparing it |
AU2014207618A1 (en) | 2013-01-16 | 2015-08-06 | Emory University | Cas9-nucleic acid complexes and uses related thereto |
RU2690183C2 (en) | 2013-09-26 | 2019-05-31 | Галдерма С.А. | Prostaglandin f2 alpha and its analogues for treating atrophic skin scarring |
US10201481B2 (en) * | 2014-03-07 | 2019-02-12 | The Procter & Gamble Company | Personal care compositions and methods of making same |
US20160184431A1 (en) | 2014-03-11 | 2016-06-30 | Promius Pharma Llc | Topical compositions comprising a corticosteroid |
US9012402B1 (en) * | 2014-06-11 | 2015-04-21 | James Blanchard | Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation |
CN104473865A (en) * | 2014-11-17 | 2015-04-01 | 重庆华邦制药有限公司 | Desonide gel and preparation method thereof |
KR20170110083A (en) | 2014-12-23 | 2017-10-10 | 인털렉츄얼 프라퍼티 어쏘시에이츠, 엘엘씨 | Methods and formulations for transdermal administration |
US10117911B2 (en) | 2015-05-29 | 2018-11-06 | Agenovir Corporation | Compositions and methods to treat herpes simplex virus infections |
JP6997624B2 (en) | 2015-06-18 | 2022-01-17 | ボシュ ヘルス ユーエス,エルエルシー. | Topical composition containing corticosteroids and retinoids for the treatment of psoriasis |
CA2992107A1 (en) | 2015-07-13 | 2017-01-19 | Dr. Reddy's Laboratories Ltd. | Topical retinoid compositions |
CN106474059A (en) * | 2015-08-27 | 2017-03-08 | 重庆华邦制药有限公司 | A kind of more stable desonide lotion of quality |
CN106474047A (en) * | 2015-08-27 | 2017-03-08 | 重庆华邦制药有限公司 | A kind of desonide preparation stable to light |
CN106474048A (en) * | 2015-08-27 | 2017-03-08 | 重庆华邦制药有限公司 | A kind of more stable desonide gel preparation of quality |
JP7032323B6 (en) | 2016-03-28 | 2023-12-18 | アラーガン、インコーポレイテッド | Phenylurea derivatives as N-formyl peptide receptor modulators |
US11812939B2 (en) | 2017-05-15 | 2023-11-14 | Cornell University | Device and system for repairing intervertebral disc herniation and methods of use |
US10779525B2 (en) | 2018-01-16 | 2020-09-22 | Zin Research LLC | Treatment compound and method of application for hoof or foot disease in animals |
US10653656B2 (en) | 2018-04-05 | 2020-05-19 | Bausch Health Ireland Limited | Topical pharmaceutical compositions for treating skin conditions |
FR3090385B1 (en) * | 2018-12-21 | 2021-01-08 | Pf Medicament | Emollient composition in the form of an emulsion |
CN111743853A (en) * | 2019-03-29 | 2020-10-09 | 天津金耀集团有限公司 | External pharmaceutical composition of near-neutral hydrocortisone butyrate |
US20220040193A1 (en) | 2020-08-04 | 2022-02-10 | Venthera, Inc. | Formulations of phosphoinositide 3-kinase inhibitors |
US20220202841A1 (en) * | 2020-12-24 | 2022-06-30 | Erine A. Kupetsky | Dermatological formulations for treatment of dermatitis |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3969516A (en) * | 1974-12-19 | 1976-07-13 | Nelson Research & Development Company | Composition and method for treatment of acne |
US4497794A (en) | 1980-12-08 | 1985-02-05 | Dermik Laboratories, Inc. | Erythromycin/benzoyl peroxide composition for the treatment of acne |
US4361584A (en) | 1977-10-07 | 1982-11-30 | A.H.C. Pharmacal, Inc. | Composition and method for the treatment of acne |
US4247547A (en) | 1979-03-19 | 1981-01-27 | Johnson & Johnson | Tretinoin in a gel vehicle for acne treatment |
US4387107A (en) | 1979-07-25 | 1983-06-07 | Dermik Laboratories, Inc. | Stable benzoyl peroxide composition |
US4692329A (en) | 1980-12-08 | 1987-09-08 | William H. Rorer, Inc. | Erythromycin/benzoyl peroxide antiacne compositions |
LU83173A1 (en) | 1981-02-27 | 1981-06-05 | Oreal | NOVEL COSMETIC COMPOSITIONS FOR THE TREATMENT OF HAIR AND SKIN CONTAINING POWDER RESULTING FROM THE SPRAYING OF AT LEAST ONE PLANT AND A COHESION AGENT |
US4514385A (en) | 1981-10-05 | 1985-04-30 | Alcon Laboratories, Inc. | Anti-acne compositions |
CH643138A5 (en) * | 1983-08-29 | 1984-05-30 | Mepha Ag | INDOMETHACIN CONTAINING, gelatinous OINTMENT. |
LU85111A1 (en) | 1983-12-01 | 1985-09-12 | Oreal | ANTI-ACNETIC COMPOSITION BASED ON BENZOYL PEROXIDE AND AT LEAST ONE SOLAR FILTER |
US5446028A (en) | 1985-12-12 | 1995-08-29 | Dermik Laboratories, Inc. | Anti-acne method and composition |
FR2604357B1 (en) | 1986-09-30 | 1988-12-02 | Oreal | PHARMACEUTICAL AND ANTI-ACNE COSMETIC COMPOSITION |
AU618517B2 (en) | 1986-12-23 | 1992-01-02 | Eugene J. Van Scott | Additives enhancing topical actions of therapeutic agents |
WO1988006888A1 (en) * | 1987-03-20 | 1988-09-22 | Curatek Pharmaceuticals, Inc. | Novel topical metronidazole formulations and therapeutic uses thereof |
MY105521A (en) * | 1989-04-17 | 1994-10-31 | Healthpoint Ltd | Moisturizing vehicle for topical application of vitamin a acid. |
CA2063576C (en) | 1989-06-07 | 1994-01-25 | Gail S. Bazzano | Slow release vehicles for minimizing skin irritancy of topical compositions |
US5122519A (en) * | 1989-06-27 | 1992-06-16 | American Cyanamid Company | Stable, cosmetically acceptable topical gel formulation and method of treatment for acne |
GB9021320D0 (en) | 1990-10-01 | 1990-11-14 | Diomed Dev Ltd | Compositions for topical application |
US5380528A (en) | 1990-11-30 | 1995-01-10 | Richardson-Vicks Inc. | Silicone containing skin care compositions having improved oil control |
JP3555762B2 (en) * | 1991-10-16 | 2004-08-18 | リチャードソン、ビックス、インコーポレーテッド | Low pH aqueous cosmetic gel containing nonionic polyacrylamide derivative |
JP3190441B2 (en) * | 1992-07-20 | 2001-07-23 | エーザイ株式会社 | Stable formulation containing azelastine hydrochloride |
US5549914A (en) * | 1992-12-14 | 1996-08-27 | Sween Corporation | Heat stable wound care gel |
CA2166062C (en) | 1993-07-01 | 2008-09-16 | Tom De Vringer | The use of non-ionic surfactants in stable topical retinoid compositions |
US5482710A (en) | 1993-07-30 | 1996-01-09 | Chesebrough-Pond'usa Co., Division Of Conopco, Inc. | Cosmetic composition for treatment of pimples and redness |
US5382432A (en) | 1993-11-15 | 1995-01-17 | Elizabeth Arden Company, Division Of Conopco, Inc. | Cosmetic method for treatment of skin |
US5466446A (en) | 1994-02-16 | 1995-11-14 | Stiefel Laboratories, Inc. | Topical compositions containing bensoyl peroxide and clindamycin and method of use thereof |
US5538732A (en) | 1994-04-12 | 1996-07-23 | Creative Products Resource, Inc. | Medicated applicator sheet for topical drug delivery |
US5451405A (en) | 1994-04-25 | 1995-09-19 | Chesebrough-Pond's Usa Co. | Skin treatment composition |
US5445823A (en) | 1994-10-20 | 1995-08-29 | The Procter & Gamble Company | Dermatological compositions and method of treatment of skin lesions therewith |
US5562917A (en) * | 1994-12-23 | 1996-10-08 | Pentech Pharmaceuticals, Inc. | Transdermal administration of apomorphine |
AT408067B (en) | 1995-03-17 | 2001-08-27 | Gebro Pharma Gmbh | PHARMACEUTICAL COMPOSITION FOR TOPICAL APPLICATION AND METHOD FOR THE PRODUCTION THEREOF |
EP0738510A3 (en) | 1995-04-20 | 2005-12-21 | L'oreal | Use of a HMG-CoA reductase inhibitor as an anti-ageing agent and as an anti-acne agent. Composition comprising at least one HMG-CoA reductase inhibitor and at least one active substance with scaling properties. |
US5750122A (en) | 1996-01-16 | 1998-05-12 | The Procter & Gamble Company | Compositions for treating hair or skin |
JP3193617B2 (en) * | 1996-01-29 | 2001-07-30 | カネボウ株式会社 | Refreshing agent and composition for human body |
US5891451A (en) | 1996-06-25 | 1999-04-06 | Elizabeth Arden Company, Division Of Conopco, Inc. | Skin treatment with salicylic acid esters |
FR2753626B1 (en) * | 1996-09-20 | 1998-11-06 | Centre International De Rech Dermatologiques Galderma Cird Galderma | NOVEL TOPICAL COMPOSITIONS IN THE FORM OF A FLUID O / W EMULSION WITH A HIGH PRO-PENETRATING GLYCOL CONTENT |
JPH1179948A (en) * | 1997-09-12 | 1999-03-23 | Noevir Co Ltd | Hair tonic and hair cosmetic, and preparation for external use for skin for suppressing sebum secretion |
US6083996A (en) * | 1997-11-05 | 2000-07-04 | Nexmed Holdings, Inc. | Topical compositions for NSAI drug delivery |
US6387383B1 (en) * | 2000-08-03 | 2002-05-14 | Dow Pharmaceutical Sciences | Topical low-viscosity gel composition |
-
2000
- 2000-08-03 US US09/632,508 patent/US6387383B1/en not_active Expired - Lifetime
-
2001
- 2001-07-24 AU AU2001279002A patent/AU2001279002B2/en active Active
- 2001-07-24 PT PT80208200T patent/PT2052714E/en unknown
- 2001-07-24 PT PT01957238T patent/PT1304992E/en unknown
- 2001-07-24 EP EP08020820.0A patent/EP2052714B1/en not_active Expired - Lifetime
- 2001-07-24 CA CA2417646A patent/CA2417646C/en not_active Expired - Lifetime
- 2001-07-24 CN CN2008100852167A patent/CN101305982B/en not_active Expired - Lifetime
- 2001-07-24 RU RU2003105831/15A patent/RU2251410C2/en active IP Right Revival
- 2001-07-24 AT AT01957238T patent/ATE429922T1/en active
- 2001-07-24 CN CN018150659A patent/CN1460013B/en not_active Expired - Lifetime
- 2001-07-24 SI SI200130926T patent/SI1304992T1/en unknown
- 2001-07-24 PL PL360589A patent/PL213237B1/en unknown
- 2001-07-24 WO PCT/US2001/023341 patent/WO2002011683A1/en active Application Filing
- 2001-07-24 KR KR1020087008303A patent/KR20080036246A/en not_active Application Discontinuation
- 2001-07-24 ES ES08020820.0T patent/ES2437321T3/en not_active Expired - Lifetime
- 2001-07-24 AU AU7900201A patent/AU7900201A/en active Pending
- 2001-07-24 ES ES01957238T patent/ES2326955T3/en not_active Expired - Lifetime
- 2001-07-24 JP JP2002517021A patent/JP4988129B2/en not_active Expired - Lifetime
- 2001-07-24 BR BR0113247-4A patent/BR0113247A/en active IP Right Grant
- 2001-07-24 DK DK08020820.0T patent/DK2052714T3/en active
- 2001-07-24 DK DK01957238T patent/DK1304992T3/en active
- 2001-07-24 EP EP01957238A patent/EP1304992B1/en not_active Expired - Lifetime
- 2001-07-24 SI SI200131027T patent/SI2052714T1/en unknown
- 2001-07-24 KR KR1020037001564A patent/KR100840169B1/en active IP Right Grant
- 2001-07-24 DE DE60138549T patent/DE60138549D1/en not_active Expired - Lifetime
- 2001-07-24 MX MXPA03001006A patent/MXPA03001006A/en active IP Right Grant
- 2001-07-24 ZA ZA200301037A patent/ZA200301037B/en unknown
- 2001-07-31 AR ARP010103660A patent/AR030093A1/en not_active Application Discontinuation
-
2002
- 2002-03-08 US US10/096,516 patent/US6517847B2/en not_active Expired - Lifetime
-
2009
- 2009-05-18 HK HK09104488.2A patent/HK1125847A1/en not_active IP Right Cessation
- 2009-06-29 CY CY20091100677T patent/CY1109189T1/en unknown
-
2013
- 2013-10-30 BE BE2013C060C patent/BE2013C060I2/nl unknown
- 2013-11-21 CY CY20131101045T patent/CY1114646T1/en unknown
-
2014
- 2014-01-23 CY CY2014005C patent/CY2014005I2/en unknown
- 2014-03-18 LU LU92401C patent/LU92401I2/en unknown
- 2014-07-04 FR FR14C0053C patent/FR14C0053I1/en active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020097211A1 (en) * | 2018-11-06 | 2020-05-14 | Cote Tim | Topical compositions comprising pentoxifylline and methods of treatment using the same |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2417646A1 (en) | Topical gel delivery system | |
CA2265461C (en) | Compositions and methods for topical application of therapeutic agents | |
JP2004505900A5 (en) | ||
US5690923A (en) | Stable topical retinoid compositions | |
RU2003105831A (en) | LOCAL APPLICATION DELIVERY SYSTEM | |
CA2299288C (en) | Non-steroidal antiinflammatory drug formulations for topical application to the skin | |
US8735393B2 (en) | Anhydrous topical skin preparations | |
US5560910A (en) | Topical anti-inflammatory composition and method | |
KR101689898B1 (en) | Topical composition for the treatment of actinic keratosis | |
US20100120918A1 (en) | Novel non-aqueous topical solution of diclofenac and process for preparing the same | |
US7618651B2 (en) | Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same | |
US8658678B2 (en) | Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water | |
US4931283A (en) | Menthol enhancement of transdermal drug delivery | |
KR950003919B1 (en) | Process for preparing topical metronidazole formulations | |
US20100029765A1 (en) | Topical aqueous composition comprising tretinoin | |
US8673356B2 (en) | Stable fixed dose topical formulation | |
PL207221B1 (en) | Dermatological formulations | |
US4487782A (en) | Topical treatment of non-inflammatory acne | |
HU225599B1 (en) | Thin adhesive plaster treated by betamethasone- and hyaluronic acid- for treatment of psoriasis, dermatitis and dermatosis | |
EP1765293B1 (en) | Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same | |
US20010019722A1 (en) | Anti-acne chrono patch | |
US20120115954A1 (en) | Aqueous retinoid and benzoyl peroxide gel | |
JPH1029937A (en) | Pharmaceutical preparation of mefenamic acid aqueous solution | |
US20120259014A1 (en) | Topical retnoid solutions | |
US4873266A (en) | Menthone enhancement of transdermal drug delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20210726 |